Cue Biopharma, Inc.
Cue Biopharma, Inc. (CUE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CUE · as of Sep 30, 2025
Ownership Breakdown
52
Institutional Holders
▲ 5 vs Q2
$12.98M
Total Inst. Value
▲ $1.13M vs Q2
2.63M
Shares Outstanding
freeFloat 99.23%
18.06M
13F Shares Held
▲ 707,215 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CUE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLEICHROEDER LP pharmaceutical preparations | 6.82M | 7.14% | 7.14% | $4.90B | Nov 14, 2025 | — held |
CATALYTIC WEALTH RIA, LLC pharmaceutical preparations | 3.43M | 3.59% | 3.59% | $2.47B | Nov 13, 2025 | ▲ 100.0K |
VANGUARD GROUP INC pharmaceutical preparations | 3.04M | 3.18% | 3.18% | $2.19B | Nov 7, 2025 | ▼ 148.0K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 800.8K | 83.89% | 83.89% | $575.60M | Nov 12, 2025 | ▲ 108.6K |
BOOTHBAY FUND MANAGEMENT, LLC pharmaceutical preparations | 611.0K | 64.00% | 64.00% | $439.10M | Nov 14, 2025 | NEW |
ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC pharmaceutical preparations | 478.5K | 50.13% | 50.13% | $343.90M | Nov 12, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 449.2K | 47.05% | 47.05% | $322.81M | Nov 12, 2025 | — held |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 324.5K | 34.00% | 34.00% | $233.00M | Feb 3, 2026 | ▼ 63 |
ADVISORY RESEARCH INC pharmaceutical preparations | 257.2K | 26.95% | 26.95% | $184.87M | Nov 13, 2025 | — held |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 227.1K | 23.79% | 23.79% | $163.19M | Nov 13, 2025 | ▲ 93.6K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+455.7K shares3
New Positions
first time holders14
Decreased
−318.6K shares0
Sold Out
fully exitedNet shares change (top 50)
+137.1K
+455.7K / −318.6K
Net new holders
-1
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CUE insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
3
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Camardo Daniel A. director | May 30, 2026 | Award | 1,626 | $21.90 | $35.6K | 1.6K | Form 4 ↗ |
Lin Shao-Lee Chief Executive Officer | Jun 1, 2026 | Purchase | 90,906 | $0.00 | $90.906 | 90.9K | Form 4 ↗ |
Lin Shao-Lee Chief Executive Officer | Jun 1, 2026 | Purchase | 45,453 | $11.00 | $500.0K | 45.5K | Form 4 ↗ |
Meehan Viola Mong director | May 30, 2026 | Award | 1,626 | $21.90 | $35.6K | 1.6K | Form 4 ↗ |
Lin Shao-Lee CHIEF EXECUTIVE OFFICER | May 3, 2026 | Award | 655,074 | $30.42 | $19.93M | 655.1K | Form 4 ↗ |
Lin Shao-Lee CHIEF EXECUTIVE OFFICER | May 3, 2026 | Award | 327,537 | — | — | 327.5K | Form 4 ↗ |
Sandercock Colin SVP, GENERAL COUNSEL | Apr 9, 2026 | Award | 200,000 | $0.29 | $58.0K | 200.0K | Form 4 ↗ |
Warren Lucinda CHIEF BUSINESS OFFICER | Apr 9, 2026 | Award | 250,000 | $0.29 | $72.5K | 250.0K | Form 4 ↗ |
Baker Daniel G. CHIEF DEVELOPMENT OFFICER | Apr 9, 2026 | Award | 100,000 | $0.29 | $29.0K | 100.0K | Form 4 ↗ |
Kiener Peter A director | Jan 2, 2026 | Award | 24,400 | $0.34 | $8.3K | 24.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cue Biopharma, Inc. (CUE) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 0.77%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Cue Biopharma, Inc. is BLEICHROEDER LP, holding approximately 6.82 million shares — equal to 7.14% of outstanding shares — as of September 30, 2025.
A total of 52 institutional investors currently hold CUE stock, with a combined institutional value of approximately $12,982,249 as of the most recent 13F filing period.
Frequently asked questions
CUE ownershipCue Biopharma, Inc. (CUE) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is BLEICHROEDER LP with a 7.14% stake. Company insiders hold 0.77%. Data sourced from SEC Form 13F as of September 30, 2025.